ASH Conference Highlights: BCMA CAR-T Therapies

This chapter reviews the recent Ash Conference in San Diego, discussing the limited significant news and the competitive dynamics between BCMA CAR-T therapy leaders, Legend Bio and Arcelix. It evaluates the safety profiles of their therapies, reflects on the implications for the future of CAR T cell therapy, and underscores the ongoing interest in the market potential for multiple myeloma treatments.